Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s Alzheimer’s EXPEDITION3 Proves Positive For Biogen’s Anti-Amyloid At CTAD

Dec 09 2016

• By Mandy Jackson

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

Nov 23 2016

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Dec 07 2016

Related Companies

Eli Lilly and Company

Biogen, Inc.

Additional Topics

Companies Clinical Trials Neurology BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window